Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.
Zacks Investment Research on MSN
Arbutus (ABUS) upgraded to buy: Here's what you should know
Arbutus Biopharma (ABUS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for ...
Arbutus Biopharma Corp. has $191 million cash giving a runway of less than 3 quarters. ABUS stock has been reporting net losses since 2013; in 2022, the net loss per share was $0.12. It maintains low ...
Asianet Newsable on MSN
ABUS stock on track for biggest intraday drop in over 5 years – what’s the issue around its patent in Europe?
The European Patent Office revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Arbutus Biopharma (ABUS) is a stock that can certainly grab the ...
We recently published a list of 10 Best Nasdaq Stocks Under $5 to Buy. In this article, we are going to take a look at where Arbutus Biopharma Corp. (NASDAQ:ABUS) stands against other best Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback